New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
07:43 EDTAAgilent price target raised to $68 from $59 at Leerink
Leerink raised its price target for Agilent shares to $68 citing the company's organic growth prospects and keeps an Outperform rating on the stock.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use